Holen Sie sich die Stockscreener-App
0.312
3.88%
-0.0126
Vorhandelsmarkt:
.30
-0.012
-3.85%
Schlusskurs vom Vortag:
$0.3246
Offen:
$0.2598
24-Stunden-Volumen:
7.30M
Relative Volume:
0.37
Marktkapitalisierung:
$11.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.52M
KGV:
-0.0413
EPS:
-7.5468
Netto-Cashflow:
$-5.72M
1W Leistung:
-8.18%
1M Leistung:
-16.35%
6M Leistung:
-73.33%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.258
$0.333
1-Wochen-Bereich:
$0.258
$0.4082
52-Wochen-Spanne:
$0.1513
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Firmenname
Lunai Bioworks Inc
Sektor
Branche
Telefon
45 39179840
Adresse
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.312 | 11.32M | 0 | -125.52M | -5.72M | -7.5468 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lunai Bioworks Inc Aktie (LNAI) Neueste Nachrichten
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus - TechStock²
A $20M Lunai deal adds two routes past the blood-brain barrier - Stock Titan
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP - Yahoo Finance
Lunai Bioworks Completes $20 Million Preferred Equity Issuance - Intellectia AI
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com
Lunai Bioworks Acquires Neurobridge IP Holdings in Major Patent-Backed Merger, Issues Series B Preferred Stock - Minichart
Lunai Bioworks Completes Merger and Issues Preferred Stock - TipRanks
Lunai Bioworks Acquires Neurobridge IP in Stock Deal, Issuing $20M Series B Preferred - TradingView
Lunai Bioworks (NASDAQ: LNAI) files proxy supplement; Reverse Split on ballot - Stock Titan
Lunai Bioworks (NASDAQ: LNAI) issues $20M preferred to acquire CNS patents, aid Nasdaq equity test - Stock Titan
Lunai Bioworks Inc. announced that it has received $20 million in funding - marketscreener.com
Why is this micro-cap biotech stock up 150% today? - MSN
What's Behind The Jump In Lunai Bioworks Stock? - MSN
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion - Quantisnow
SKAGI: Uppfærðar áherslur og skipulagsbreytingar - Weekly Voice
Lunai Bioworks, Inc. Announces Postponement of Special Meeting of Stockholders to May 8, 2026 - Weekly Voice
Lunai Bioworks Postpones Special Stockholder Meeting to May 8, 2026 to Ensure Quorum and Broker Voting Compliance 1 - Minichart
Lunai Bioworks Delays Special Stockholder Meeting to May - TipRanks
Lunai Bioworks (NASDAQ: LNAI) moves special vote to May 8 - Stock Titan
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Quantisnow
2 biotech stocks bridging the gap between unmet need and next-gen medicine - MSN
Lunai Bioworks completes $20M transaction to acquire BBB - MSN
2 biotech stocks bridging the gap between unmet need and next-gen medicine | 2026-04-27 | Investing News - Stockhouse
Is Lunai Bioworks (LNAI) stock gaining bullish momentum |Beat Estimates - Newser
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED) - MSN
LNAI Lunai Bioworks reports Q1 2026 EPS of negative 8 cents with no consensus estimates, notching a 1.77 percent share gain today.Earnings Miss - Newser
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED) - Benzinga
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension - Benzinga
LNAI Should I Buy - Intellectia AI
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Is Lunai Bioworks (LNAI) stock a strong buy | Q1 2026: Earnings ReportExpert Momentum Signals - Xã Thanh Hà
Lunai Bioworks (LNAI) Stock Fill Price (Investor Concern) 2026-04-20Momentum Surge - Cổng thông tin điện tử tỉnh Lào Cai
Lunai Bioworks unit secures defense collaboration for AI chemical threat platform - MSN
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships - Sahm
Lunai Bioworks signs letter of intent with Geneial for rare disease data collaboration - Investing.com Australia
Reverse split range 1-for-3 to 1-for-30 proposed by Lunai Bioworks (NASDAQ: LNAI) - Stock Titan
Finanzdaten der Lunai Bioworks Inc-Aktie (LNAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):